Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
138 hedge funds and large institutions have $274M invested in Insys Therapeutics, Inc. in 2016 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 41 increasing their positions, 49 reducing their positions, and 21 closing their positions.
10% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 21
0% more funds holding
Funds holding: 138 → 138 (0)
16% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 49
29% less capital invested
Capital invested by funds: $383M → $274M (-$109M)
52% less call options, than puts
Call options by funds: $3.44M | Put options by funds: $7.11M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$6.43M |
| 2 |
RIA
Regal Investment Advisors
Kentwood,
Michigan
|
+$2.59M |
| 3 |
AC
Ascend Capital
Orinda,
California
|
+$2.54M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.84M |
| 5 |
Credit Agricole
Montrouge Cedex,
France
|
+$1.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$22.6M |
| 2 |
State Street
Boston,
Massachusetts
|
-$8.87M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.26M |
| 4 |
FCM
Freshford Capital Management
Rye Brook,
New York
|
-$4.51M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$3.56M |
INSY Hedge Fund Activity: Q4 2016 in Review
138 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q4 2016, worth a combined $274M — down 29% from $383M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new INSY positions and 21 closed out — a net gain of 2 holders — while 41 added to existing stakes and 49 trimmed.
The largest buyer was OrbiMed, adding an estimated $6.43M. The largest seller was Scopia Capital Management, cutting an estimated $22.6M.
- 138 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $274M of Insys Therapeutics, Inc. stock for Q4 2016, down 29% quarter-over-quarter.
- 23 funds opened new Insys Therapeutics, Inc. positions in Q4 2016 and 21 closed out, a net change of +2 holders.
- The largest Insys Therapeutics, Inc. buyer in Q4 2016 was OrbiMed, an estimated $6.43M added.
- The largest Insys Therapeutics, Inc. seller in Q4 2016 was Scopia Capital Management, an estimated $22.6M sold.
Based on aggregated 13F filings for Q4 2016.